摘要:
This invention relates to a combination of immunotherapy and chemotherapy to promote tumor regression by treating a patient in need thereof with a combination of a humanized antibody that binds to A33 antigen and one or more chemotherapeutic agents. The method is useful for treating patients with colorectal cancer and gastric carcinomas. The method is particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
摘要:
The invention is directed to methods of reducing the effects of cancer in a subject by administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an inmmunoglobulin product which comprises one or more novel complementarity determining region and framework regions.
摘要:
The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.
摘要:
The invention involves the therapeutic use of humanized antibodies, fragments, etc., which bind to the antigen A33. These antibody molecules are useful in the treatment of various neoplasias, including colon cancer. Various modes of administration, and doses are described.
摘要:
The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
摘要:
The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.
摘要:
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
摘要:
The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.
摘要:
This invention relates to isolated protein and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.
摘要:
The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.